Message from the SVP

Dear Friends,

Progress at Greenwich Hospital is recognized by enhanced patient care, and I am delighted to share exciting updates with our friends and supporters.

We warmly welcome Robert (Bob) Blenderman, PA, MBA, as the new president of Greenwich Hospital and executive vice president of Yale New Haven Health. Bob assumes the helm of Greenwich Hospital with more than two decades of clinical and administrative healthcare experience, which will further advancement across various clinical specialties important to the communities we serve.

One of those areas is oncology. We know that cancer care cannot wait, which is why Greenwich Hospital has made the expansion of our oncology program a priority within the $125 million Arc of Care Campaign. Funding from our generous donors makes possible expert leadership, state-of-the-art equipment and innovative research.

Our Oncology program is guided by William K. Oh, MD, newly appointed medical director of Smilow Cancer Hospital at Greenwich Hospital. He is a physician-scientist and genitourinary oncologist, with decades of experience caring for patients with prostate cancer. In addition to his leadership in Greenwich, Dr. Oh is the director of precision medicine for Yale Cancer Center and Smilow Cancer Hospital, focused on building a cohesive program in precision medicine that integrates basic and translational science, clinical trials and Smilow Cancer Hospital’s Precision Medicine Tumor Board.

Greenwich Hospital is investing in cutting-edge equipment. Our breast cancer surgeons are using the new Hologic Trident®, an HD specimen radiography system that provides detailed images for tissue sample verification during lumpectomy procedures. The newly acquired Delta4 Phantom+ enables our radiation oncologists to measure, with great accuracy, how much radiation is delivered to tissue.

Research stemming from Yale School of Medicine into developing a blood test that measures circulating tumor DNA (ctDNA) is currently being offered at Greenwich Hospital to evaluate if women who complete chemotherapy, but who have residual triple negative breast cancer at the time of surgery, are at higher risk for recurrence. The research is to determine whether this blood test is more effective than mammograms, ultrasounds and physical exams. So far, eight women have been identified with positive ctDNA tests and found to have metastatic breast cancer on scans that otherwise could have been missed.

Our Office of Development is hosting The Future of Cancer Care: New Innovations, Earlier Detection and Better Outcomes on April 3 at the Bruce Museum. This interactive event will feature Dr. Oh, and I invite you to join us for an evening of learning and conversation, which will also provide an opportunity to meet our new hospital president.

Space is limited. RSVP before March 24. Register by phone at 203-863-3853. Register online at Oncology.GiveSmart.com.

To learn more about progress at Greenwich Hospital, please contact me directly.

With much gratitude,

Noël Appel
Senior Vice President and Chief Development Officer
Greenwich Hospital Office of Development
203-863-3861
Noel.Appel@greenwichhospital.org